Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots.
antigen-specific T cells
biomaterial-based scaffolds
cancer vaccination
dendritic cells
nanoparticles
Journal
ACS biomaterials science & engineering
ISSN: 2373-9878
Titre abrégé: ACS Biomater Sci Eng
Pays: United States
ID NLM: 101654670
Informations de publication
Date de publication:
13 12 2021
13 12 2021
Historique:
pubmed:
5
11
2021
medline:
27
1
2022
entrez:
4
11
2021
Statut:
ppublish
Résumé
Synthetic cancer vaccines may boost anticancer immune responses by co-delivering tumor antigens and adjuvants to dendritic cells (DCs). The accessibility of cancer vaccines to DCs and thereby the delivery efficiency of antigenic material greatly depends on the vaccine platform that is used. Three-dimensional scaffolds have been developed to deliver antigens and adjuvants locally in an immunostimulatory environment to DCs to enable sustained availability. However, current systems have little control over the release profiles of the cargo that is incorporated and are often characterized by an initial high-burst release. Here, an alternative system is designed that co-delivers antigens and adjuvants to DCs through cargo-loaded nanoparticles (NPs) incorporated within biomaterial-based scaffolds. This creates a programmable system with the potential for controlled delivery of their cargo to DCs. Cargo-loaded poly(d,l-lactic-
Identifiants
pubmed: 34734689
doi: 10.1021/acsbiomaterials.0c01648
pmc: PMC8672349
doi:
Substances chimiques
Cancer Vaccines
0
Polyglycolic Acid
26009-03-0
Lactic Acid
33X04XA5AT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5622-5632Références
J Clin Invest. 2018 Apr 2;128(4):1338-1354
pubmed: 29480817
Int J Nanomedicine. 2016 Aug 05;11:3753-64
pubmed: 27540289
Adv Immunol. 2006;90:215-41
pubmed: 16730265
Nat Commun. 2015 Aug 12;6:7556
pubmed: 26265369
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Nat Mater. 2009 Feb;8(2):151-8
pubmed: 19136947
ACS Nano. 2013 May 28;7(5):3912-25
pubmed: 23590591
Nanomedicine (Lond). 2017 Mar;12(5):491-510
pubmed: 28181470
Nat Rev Immunol. 2018 Mar;18(3):212-219
pubmed: 28853444
Vaccine. 2003 Mar 7;21(11-12):1250-5
pubmed: 12559806
Trends Immunol. 2016 Dec;37(12):855-865
pubmed: 27793569
Annu Rev Cell Dev Biol. 1996;12:697-715
pubmed: 8970741
Trends Biotechnol. 2020 Apr;38(4):418-431
pubmed: 31699534
Front Immunol. 2018 Nov 28;9:2798
pubmed: 30546367
Hum Vaccin Immunother. 2014;10(11):3261-9
pubmed: 25625929
J Immunother. 2008 Sep;31(7):620-32
pubmed: 18600182
Cancer Immunol Immunother. 2009 Jan;58(1):145-51
pubmed: 18392619
Nanomedicine. 2010 Oct;6(5):651-61
pubmed: 20348031
Int J Nanomedicine. 2014 Nov 12;9:5231-46
pubmed: 25419128
Oncoimmunology. 2015 Aug 12;5(1):e1068493
pubmed: 26942088
Immunology. 2006 Jan;117(1):78-88
pubmed: 16423043
Blood. 2011 Dec 22;118(26):6836-44
pubmed: 21967977
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19590-5
pubmed: 23150549
Nat Mater. 2018 Jun;17(6):528-534
pubmed: 29507416
Clin Transl Immunology. 2016 Mar 18;5(3):e66
pubmed: 27217957
Bioconjug Chem. 2018 Mar 21;29(3):733-741
pubmed: 29318872
Cancer Immunol Immunother. 2007 Aug;56(8):1251-64
pubmed: 17242927
J Exp Med. 2000 Mar 6;191(5):795-804
pubmed: 10704461
Adv Healthc Mater. 2019 Mar;8(5):e1800571
pubmed: 30680955
ACS Cent Sci. 2020 Oct 28;6(10):1800-1812
pubmed: 33145416
Adv Mater. 2018 May;30(18):e1706719
pubmed: 29572968
Nat Biotechnol. 2015 Jan;33(1):64-72
pubmed: 25485616
J Control Release. 2002 Dec 13;85(1-3):247-62
pubmed: 12480329
Biomaterials. 2003 Nov;24(24):4385-415
pubmed: 12922151
J Am Chem Soc. 2013 Feb 13;135(6):2044-7
pubmed: 23331082
Small. 2018 Apr;14(15):e1703539
pubmed: 29493121